| Senescence surveillance of pre-malignant hepatocytes limits liver cancer development TW Kang, T Yevsa, N Woller, L Hoenicke, T Wuestefeld, D Dauch, ... Nature 479 (7374), 547-551, 2011 | 1556 | 2011 |
| A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage J Wang, Q Sun, Y Morita, H Jiang, A Groß, A Lechel, K Hildner, ... Cell 148 (5), 1001-1014, 2012 | 375 | 2012 |
| Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer M Malehmir, D Pfister, S Gallage, M Szydlowska, D Inverso, E Kotsiliti, ... Nature medicine 25 (4), 641-655, 2019 | 318 | 2019 |
| In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer R Rudalska, D Dauch, T Longerich, K McJunkin, T Wuestefeld, TW Kang, ... Nature medicine 20 (10), 1138-1146, 2014 | 302 | 2014 |
| A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer D Dauch, R Rudalska, G Cossa, JC Nault, TW Kang, T Wuestefeld, ... Nature medicine 22 (7), 744-753, 2016 | 272 | 2016 |
| Cardiac glycosides are broad-spectrum senolytics A Guerrero, N Herranz, B Sun, V Wagner, S Gallage, R Guiho, K Wolter, ... Nature metabolism 1 (11), 1074-1088, 2019 | 249 | 2019 |
| A critical role for notch signaling in the formation of cholangiocellular carcinomas S Zender, I Nickeleit, T Wuestefeld, I Sörensen, D Dauch, P Bozko, ... Cancer cell 23 (6), 784-795, 2013 | 235 | 2013 |
| A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration T Wuestefeld, M Pesic, R Rudalska, D Dauch, T Longerich, TW Kang, ... Cell 153 (2), 389-401, 2013 | 166 | 2013 |
| IGF2 is up-regulated by epigenetic mechanisms in hepatocellular carcinomas and is an actionable oncogene product in experimental models I Martinez-Quetglas, R Pinyol, D Dauch, S Torrecilla, V Tovar, A Moeini, ... Gastroenterology 151 (6), 1192-1205, 2016 | 120 | 2016 |
| Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours E Brenner, BF Schörg, F Ahmetlić, T Wieder, FJ Hilke, N Simon, ... Nature Communications 11 (1), 1335, 2020 | 95 | 2020 |
| Spatial tissue proteomics quantifies inter-and intratumor heterogeneity in hepatocellular carcinoma (HCC) K Buczak, A Ori, JM Kirkpatrick, K Holzer, D Dauch, S Roessler, V Endris, ... Molecular & Cellular Proteomics 17 (4), 810-825, 2018 | 79 | 2018 |
| Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling T Pantsar, S Rissanen, D Dauch, T Laitinen, I Vattulainen, A Poso PLoS computational biology 14 (9), e1006458, 2018 | 74 | 2018 |
| Nucleoporin Nup155 is part of the p53 network in liver cancer K Holzer, A Ori, A Cooke, D Dauch, E Drucker, P Riemenschneider, ... Nature communications 10 (1), 2147, 2019 | 39 | 2019 |
| Proteomic analysis reveals GMP synthetase as p53 repression target in liver cancer K Holzer, E Drucker, S Roessler, D Dauch, F Heinzmann, N Waldburger, ... The American journal of pathology 187 (2), 228-235, 2017 | 37 | 2017 |
| Prosurvival function of the cellular apoptosis susceptibility/importin‐α1 transport cycle is repressed by p53 in liver cancer J Winkler, A Ori, K Holzer, C Sticht, D Dauch, EM Eiteneuer, F Pinna, ... Hepatology 60 (3), 884-895, 2014 | 35 | 2014 |
| Optimized Target Residence Time: Type I Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R‐Spine HK Wentsch, NM Walter, M Bührmann, S Mayer‐Wrangowski, D Rauh, ... Angewandte Chemie International Edition 56 (19), 5363-5367, 2017 | 30 | 2017 |
| LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer R Rudalska, J Harbig, MT Snaebjornsson, S Klotz, S Zwirner, L Taranets, ... Nature cancer 2 (2), 201-217, 2021 | 27 | 2021 |
| Selective targeting of the αC and DFG-out pocket in p38 MAPK S Roehm, M Schroeder, JE Dwyer, CS Widdowson, A Chaikuad, ... European Journal of Medicinal Chemistry 208, 112721, 2020 | 13 | 2020 |
| MYC determines lineage commitment in KRAS-driven primary liver cancer development L D’Artista, AA Moschopoulou, I Barozzi, AJ Craig, M Seehawer, ... Journal of Hepatology 79 (1), 141-149, 2023 | 6 | 2023 |
| HELLS is negatively regulated by wild-type P53 in liver cancer by a mechanism involving P21 and FOXM1 S Schuller, J Sieker, P Riemenschneider, B Köhler, E Drucker, ... Cancers 14 (2), 459, 2022 | 6 | 2022 |
